Druggists' preparations (pharmaceuticals)
Phoenix Pharmalabs Inc
Phoenix Pharmalabs Inc, based in Providence, UT, is a pre-clinical pharmaceutical company dedicated to developing potent pain therapies with minimal risk of addiction and serious side effects. Their lead candidate, PPL-138, offers 100 times the potency of morphine with low abuse potential and no respiratory depression, while their second drug candidate, PPL-103, shows promise for treating addiction and pain with reduced opioid side effects. With over $23 million in funding from sources like the U.S. Army and NIH NIDA, Phoenix Pharmalabs aims to address the unmet medical need for safe pain management by creating drugs that provide effective pain relief without the harmful consequences associated with traditional opioids. Their innovative approach targets the $30 billion opioid therapeutics market, offering hope for a safer alternative to current pain management options.Generated from the website